Novo Nordisk’s CEO told CNN he is “alarmed” by the risks compounded versions of semaglutide — the active ingredient in the company’s diabetes drug Ozempic and weight loss drug Wegovy — are posing to users.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
